DTB Podcast

BMJ Podcasts
  • 0,0 (0)
  • MÉDECINE
  • TOUS LES MOIS

The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing. Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue. DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals. Subscribe to the DTB Podcast and get the latest drug and therapeutic insights.

  1. 3 FÉVR.

    GLP-1 drugs, reducing sedative use, and a thank you

    In this podcast accompanying the February 2026 issue of the DTB (https://dtb.bmj.com/content/64/2), Syba Sunny (DTB Clinical Editor) is joined by Julian Treadwell (DTB Associate Editor). Syba and Julian start by talking about this month’s ‘thank you’ editorial (https://dtb.bmj.com/content/64/2/18) before delving into the hot topic of GLP-1 drugs for the treatment of obesity, which is the subject of a DTB review article that summarises what is known about their benefits and harms (https://dtb.bmj.com/content/64/2/19). Finally, they discuss an intervention to reduce sedative use in patients who have been taking these drugs for a long time (https://dtb.bmj.com/content/64/2/25).

    29 min

  2. 6 JANV.

    Disinformation and misinformation, AI in primary care and antidepressant tapering

    In this podcast accompanying the January 2026 issue of the DTB (https://dtb.bmj.com/content/64/1), Syba Sunny (DTB Clinical Editor) is joined by Tom Nolan, an NHS general practitioner and Clinical Editor at BMJ Medicine. Syba and Tom first talk through this month’s editorial on disinformation and misinformation (https://dtb.bmj.com/content/64/1/2), and discuss ways to combat these in medicine. They then provide an overview of a DTB Forum article, which explains the benefits of taking people off antidepressants using the hyperbolic tapering method (https://dtb.bmj.com/content/64/1/3). The episode ends with Tom sharing his thoughts about the role of artificial intelligence (AI) in primary care.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email dtb@bmj.com. Thank you for listening.

    21 min

  3. 03/12/2025

    Prevention in primary care, elinzanetant for menopause, and a farewell to David.

    In this podcast accompanying the December issue of the DTB  (https://dtb.bmj.com/content/63/12), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss this month’s editorial, written by Julian Treadwell, academic GP and DTB editorial board member, which delves into the challenges of prioritising preventative medicine in primary care (https://dtb.bmj.com/content/63/12/178). They then talk about a review article that provides an overview of the new drug elinzanetant, a non-hormonal treatment for vasomotor symptoms associated with menopause (https://dtb.bmj.com/content/63/12/182). Finally, the journal bids an emotional farewell to David, who is retiring after many good years at the DTB. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email dtb@bmj.com. Thank you for listening.

    16 min

  4. 03/11/2025

    Medicines - but at what cost, direct penicillin allergy challenge, and prescribing mistakes

    In this podcast accompanying the November issue of DTB (https://dtb.bmj.com/content/63/11) David Phizackerley (DTB Editor) is joined by Syba Sunny (DTB Clinical Editor). David and Syba discuss the editorial that argues that NHS budgets should not be used to ensure that pharmaceutical companies invest in the UK (https://dtb.bmj.com/content/63/11/162). They talk about a DTB Select article that summarises a systematic review and meta-analysis of trials that assessed patients with a reported penicillin or beta-lactam allergy who underwent direct oral penicillin challenge (https://dtb.bmj.com/content/63/11/163). They finish by discussing the main article that explores the intersection of medication errors, prescribing errors, harms resulting from the use of medicines and some legal consequences (https://dtb.bmj.com/content/63/11/168).   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

    20 min

  5. 01/10/2025

    Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy

    In this podcast accompanying the October issue of DTB (https://dtb.bmj.com/content/63/10) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice (https://dtb.bmj.com/content/63/10/146). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout (https://dtb.bmj.com/content/63/10/147). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (https://dtb.bmj.com/content/63/10/150).   Links GP Evidence: https://gpevidence.org/ Preventing Overdiagnosis 2025 International Conference: https://www.cebm.ox.ac.uk/preventing-overdiagnosis   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

    30 min

  6. 05/09/2025

    Antibiotic susceptibility reports, deprescribing, and heart failure drugs

    In this podcast accompanying the September issue of DTB (https://dtb.bmj.com/content/63/9), David Phizackerley (DTB Editor) is joined by Syba Sunny (DTB Clinical Editor). David and Syba discuss the editorial that highlights changes to antibiotic susceptibility reports, and in particular, the change to the 'I' classification from 'intermediate' to 'susceptible, increased exposure’ (https://dtb.bmj.com/content/63/9/130). They talk about a DTB Select article that summarises an evidence review of deprescribing interventions in primary care and the importance of collaborative multidisciplinary teams, education and training, and shared-decision making (https://dtb.bmj.com/content/63/9/131). They finish by discussing the main article that provides an overview of pharmacological management of chronic heart failure with reduced ejection fraction and the four main groups of drugs that form the four pillars of treatment (https://dtb.bmj.com/content/63/9/133).   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

    18 min

  7. 31/07/2025

    AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease

    In this podcast accompanying the August issue of DTB (https://dtb.bmj.com/content/63/8), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) (https://dtb.bmj.com/content/63/8/114) which looks at the role of AI in publishing. They talk about a DTB Forum article (https://dtb.bmj.com/content/63/8/115) that explores some of the practical problems of implementing drug safety alerts.  A DTB Select article (https://dtb.bmj.com/content/63/8/117) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article (https://dtb.bmj.com/content/63/8/118) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease.   Link BMJ policy on AI use: https://www.bmj.com/content/ai-use    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

    39 min

  8. 01/07/2025

    National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

    In this podcast accompanying the July issue of DTB  (https://dtb.bmj.com/content/63/7), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss the editorial (https://dtb.bmj.com/content/63/7/98) which focuses on some key changes in the new national asthma guideline and the implications for patients and healthcare professionals. A DTB Select article (https://dtb.bmj.com/content/63/7/99) provides an overview of a double-blind randomised placebo-controlled trial that assessed whether bisoprolol reduced the number of exacerbations in people with COPD. The main article (https://dtb.bmj.com/content/63/7/103) is an overview of abaloparatide, which is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.   The podcast begins with a discussion about ideas for new articles for DTB and the therapeutic areas currently under consideration. If you have a suggestion for an article that you would like DTB to cover, please email details to dtb@bmj.com.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

    23 min
Tout afficher (187)

À propos

The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing. Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue. DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals. Subscribe to the DTB Podcast and get the latest drug and therapeutic insights.

Informations

  • Chaîne
    BMJ Podcasts
  • Création
    BMJ Group
  • Années d’activité
    2009 - 2026
  • Épisodes
    187
  • Classification
    Tous publics
  • Copyright
    © Copyright 2023 All rights reserved.
  • Site web de l’émission
    DTB Podcast

Plus de contenus par BMJ Podcasts

Vous aimeriez peut‑être aussi